Morris Peter E, Hite R Duncan, Ohl Christopher
Division of Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27104, USA.
BioDrugs. 2002;16(6):403-17. doi: 10.2165/00063030-200216060-00002.
In patients with severe sepsis, thrombin has been implicated in the interrelationship between the coagulation and inflammation pathways. Thrombin is responsible for conversion of fibrinogen to fibrin (thrombus formation). Thrombin also activates endothelial cells, white blood cells and platelets. Regulation of both the coagulation and inflammation pathways is in part through the interaction of thrombin and activated protein C. Activated protein C has particular attributes that may inhibit microvascular thrombi, promote fibrinolysis and directly dampen the pro-inflammatory aspect of infection. In patients with severe sepsis, many investigators have demonstrated an active coagulopathic state, with low protein C levels. A phase III clinical trial has now demonstrated reduced mortality in patients with severe sepsis receiving activated protein C.
在严重脓毒症患者中,凝血酶与凝血和炎症途径之间的相互关系有关。凝血酶负责将纤维蛋白原转化为纤维蛋白(血栓形成)。凝血酶还可激活内皮细胞、白细胞和血小板。凝血和炎症途径的调节部分是通过凝血酶与活化蛋白C的相互作用实现的。活化蛋白C具有特定属性,可能抑制微血管血栓形成、促进纤维蛋白溶解并直接减轻感染的促炎方面。在严重脓毒症患者中,许多研究人员已证明存在一种活跃的凝血病状态,蛋白C水平较低。一项III期临床试验现已证明,接受活化蛋白C治疗的严重脓毒症患者死亡率降低。